

# Initial Prior Authorization

## Kerendia

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Kerendia	finerenone

### Indications

#### FDA-approved Indications

Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

### Coverage Criteria

#### Chronic Kidney Disease (CKD) Associated with Type 2 Diabetes (T2D)

Authorization may be granted when the patient has a diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) when ONE of the following criteria are met:

- The patient is currently receiving a maximally tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) OR angiotensin receptor blocker (ARB).
- The patient has experienced an intolerance to an ACEi or ARB.
- The patient has a contraindication that would prohibit a trial of an ACEi or ARB.

Reference number(s)
4871-A

## Duration of Approval (DOA)

- 4871-A: DOA: 12 months

## References

1. Kerendia [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; September 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed September 24, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 09/24/2024).
4. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes – 2023. Diabetes Care. Dec 2022;46:S191-S202.
5. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(Suppl 5S):S1-S127.